Find your care

Our experienced ILD specialists deliver comprehensive care to improve your health and quality of life. Call 310-825-8061 to connect with an expert.

The UCLA ILD research program is a collaborative effort among patients, providers and scientists. The program has several types of interstitial lung disease research:

  • Clinical Research —Clinical research includes both observational studies and clinical trials that use the knowledge gained in basic research to study the benefits of new drugs.
  • Database/registry — The UCLA ILD registry has an ongoing longitudinal research database and biorepository study. This database is a rich source of data and biologic specimens for 



  • Basic research — Experimental work carried out in a laboratory helps the center to increase understanding of the fundamental cellular mechanisms of interstitial lung disease.

Patients may be asked if they are interested in participating in a research study. Participation is voluntary. The choice of whether or not to participate in a research study will not impact patient care in any way. Research funding comes from a variety of public and private sources.

Give to ILD Center

To become involved in a research study Speak with the physicians in the UCLA Interstitial Lung Disease Center about your available options.

For additional information, contact Eileen Callahan at [email protected]

Studies Currently Enrolling


Prospective Outcomes Registry of Subjects with a non- IPF Interstitial Lung Disease of any duration. This registry will collect data on the strategies used to achieve a diagnosis of Interstitial Lung Disease (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient-reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts.

FGCL-3019-091 (Fibrogen)

A Phase 3 Randomized, Double-Blind, Placebo- Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).

Studies Coming Soon


A Phase 3 Randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis

PLN-74809-IPF-202 (Pliant)

A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis  (INTEGRIS-IPF)

United Therapeutics (Teton)

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

Active Studies No Longer Enrolling

BMS IM027040

 A Multicenter, Randomized, Double blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis


An open label extension trial to assess the long-term safety of Nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease


An open label extension trial of the long-term safety of Nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

 Pulmonary Fibrosis Foundation Patient Registry

This is a nationwide patient registry and biorepository for patients with pulmonary fibrosis. It is a collection of information about PF patients, including their diagnosis and how it was made, lab and test results, medications taken, and medical outcomes such as hospitalization, lung transplantation, and death. Participants are asked to answer questions about their health, their PF symptoms, and how it affects their lives. Participants may choose to contribute, at the time they enroll, blood samples to a biorepository that will store them for use in future research. When combined with the information in the Registry, these samples will help scientists find new causes of PF, identify means of determining whether treatments are working, improve the ways doctors manage the disease, and help discover new treatments.


Combining the anti-fibrotic effects of Pirfenidone (PFD) with Mycophenolate (MMF) for treating scleroderma-related interstitial lung disease.